Skip to main content
Erschienen in: Strahlentherapie und Onkologie 1/2015

01.01.2015 | Original article

Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity

verfasst von: Sebastian Reuther, PhD, Silke Szymczak, PhD, Annette Raabe, PhD, Kerstin Borgmann, PhD, Andreas Ziegler, PhD, Cordula Petersen, MD, Prof Dr. Ekkehard Dikomey, PhD, Ulrike Hoeller, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

The aim of this study was to determine the impact of functional single nucleotide polymorphism (SNP) pathways involved in the ROS pathway, DNA repair, or TGFB1 signaling on acute or late normal toxicity as well as individual radiosensitivity.

Materials and methods

Patients receiving breast-conserving surgery and radiotherapy were examined either for erythema (n = 83), fibrosis (n = 123), or individual radiosensitivity (n = 123). The 17 SNPs analyzed are involved in the ROS pathway (GSTP1, SOD2, NQO1, NOS3, XDH), DNA repair (XRCC1, XRCC3, XRCC6, ERCC2, LIG4, ATM) or TGFB signaling (SKIL, EP300, APC, AXIN1, TGFB1). Associations with biological and clinical endpoints were studied for single SNPs but especially for combinations of SNPs assuming that a SNP is either beneficial or deleterious and needs to be weighted.

Results

With one exception, no significant association was seen between a single SNP and the three endpoints studied. No significant associations were also observed when applying a multi-SNP model assuming that each SNP was deleterious. In contrast, significant associations were obtained when SNPs were suggested to be either beneficial or deleterious. These associations increased, when each SNP was weighted individually. Detailed analysis revealed that both erythema and individual radiosensitivity especially depend on SNPs affecting DNA repair and TGFB1 signaling, while SNPs in ROS pathway were of minor importance.

Conclusion

Functional pathways of SNPs may be used to form a risk score allowing to predict acute and late radiation-induced toxicity but also to unravel the underlying biological mechanisms.
Literatur
1.
Zurück zum Zitat Alsbeih G, Al-Harbi N, Al-Hadyan K et al (2010) Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res 173:505–511PubMedCrossRef Alsbeih G, Al-Harbi N, Al-Hadyan K et al (2010) Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res 173:505–511PubMedCrossRef
2.
Zurück zum Zitat Alsner J, Andreassen CN, Overgaard J (2008) Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 18:126–135PubMedCrossRef Alsner J, Andreassen CN, Overgaard J (2008) Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 18:126–135PubMedCrossRef
3.
Zurück zum Zitat Andreassen CN, Alsner J, Overgaard J (2002) Does variability in normal tissue reactions after radiotherapy have a genetic basis–where and how to look for it?. Radiother Oncol 64:131–140PubMedCrossRef Andreassen CN, Alsner J, Overgaard J (2002) Does variability in normal tissue reactions after radiotherapy have a genetic basis–where and how to look for it?. Radiother Oncol 64:131–140PubMedCrossRef
4.
Zurück zum Zitat Andreassen CN, Alsner J, Overgaard M et al (2003) Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69:127–35PubMedCrossRef Andreassen CN, Alsner J, Overgaard M et al (2003) Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69:127–35PubMedCrossRef
5.
Zurück zum Zitat Angele S, Romestaing P, Moullan N et al (2003) ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 63:8717–8725PubMed Angele S, Romestaing P, Moullan N et al (2003) ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 63:8717–8725PubMed
6.
Zurück zum Zitat Azria D, Ozsahin M, Kramar A et al (2008) Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 14:6284–6288PubMedCentralPubMedCrossRef Azria D, Ozsahin M, Kramar A et al (2008) Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 14:6284–6288PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Azria D, Betz M, Bourgier C et al (2012) Identifying patients at risk for late radiation-induced toxicity. Crit Rev Oncol Hematol 84(Suppl 1):e35–e41. Azria D, Betz M, Bourgier C et al (2012) Identifying patients at risk for late radiation-induced toxicity. Crit Rev Oncol Hematol 84(Suppl 1):e35–e41.
8.
Zurück zum Zitat Barnett GC, Coles CE, Elliott RM et al (2012) Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13:65–77PubMedCrossRef Barnett GC, Coles CE, Elliott RM et al (2012) Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13:65–77PubMedCrossRef
9.
Zurück zum Zitat Barnett GC, Elliott RM, Alsner J et al (2012) Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 105:289–295PubMedCentralPubMedCrossRef Barnett GC, Elliott RM, Alsner J et al (2012) Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 105:289–295PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Borgmann K, Hoeller U, Nowack S et al (2008) Individual radiosensitivity measured with lymphocytes may predict the risk of acute reaction after radiotherapy. Int J Radiat Oncol Biol Phys 71:256–264PubMedCrossRef Borgmann K, Hoeller U, Nowack S et al (2008) Individual radiosensitivity measured with lymphocytes may predict the risk of acute reaction after radiotherapy. Int J Radiat Oncol Biol Phys 71:256–264PubMedCrossRef
11.
Zurück zum Zitat Cesaretti JA, Stock RG, Lehrer S et al (2005) ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61:196–202PubMedCrossRef Cesaretti JA, Stock RG, Lehrer S et al (2005) ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61:196–202PubMedCrossRef
12.
Zurück zum Zitat Castiglia D, Bernardini S, Alvino E et al (2008) Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosomes Cancer 47:614–624PubMedCrossRef Castiglia D, Bernardini S, Alvino E et al (2008) Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosomes Cancer 47:614–624PubMedCrossRef
13.
Zurück zum Zitat Chang-Claude J, Popanda O, Tan XL et al (2005) Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11:4802–4809PubMedCrossRef Chang-Claude J, Popanda O, Tan XL et al (2005) Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11:4802–4809PubMedCrossRef
14.
Zurück zum Zitat Chang-Claude J, Ambrosone CB, Lilla C et al (2009) Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 100:1680–1686PubMedCentralPubMedCrossRef Chang-Claude J, Ambrosone CB, Lilla C et al (2009) Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 100:1680–1686PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat De Ruyck K, Van Eijkeren M, Claes K et al (2006) TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 65:1240–1248PubMedCrossRef De Ruyck K, Van Eijkeren M, Claes K et al (2006) TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 65:1240–1248PubMedCrossRef
16.
Zurück zum Zitat Dikomey E (2013) Predictive marker for acute normal tissue toxity in radiotherapy of non-small cell lung cancer. Strahlenther Onkol 189:806–808PubMedCrossRef Dikomey E (2013) Predictive marker for acute normal tissue toxity in radiotherapy of non-small cell lung cancer. Strahlenther Onkol 189:806–808PubMedCrossRef
17.
Zurück zum Zitat Dikomey E, Borgmann K, Brammer I et al (2003) Molecular mechanisms of individual radiosensitivity studied in normal diploid human fibroblasts. Toxicology 193:125–135PubMedCrossRef Dikomey E, Borgmann K, Brammer I et al (2003) Molecular mechanisms of individual radiosensitivity studied in normal diploid human fibroblasts. Toxicology 193:125–135PubMedCrossRef
18.
Zurück zum Zitat Dikomey E, Dahm-Daphi J, Distel L (2012) Prediction of the reaction of normal tissue and tumor cells to radiotherapy. Strahlenther Onkol 188(Suppl 3):304–307PubMedCrossRef Dikomey E, Dahm-Daphi J, Distel L (2012) Prediction of the reaction of normal tissue and tumor cells to radiotherapy. Strahlenther Onkol 188(Suppl 3):304–307PubMedCrossRef
19.
Zurück zum Zitat Ghazali N, Shaw RJ, Rogers SN et al (2012) Genomic determinants of normal tissue toxicity after radiotherapy for head and neck malignancy: a systematic review. Oral Oncol 48:1090–1100PubMedCrossRef Ghazali N, Shaw RJ, Rogers SN et al (2012) Genomic determinants of normal tissue toxicity after radiotherapy for head and neck malignancy: a systematic review. Oral Oncol 48:1090–1100PubMedCrossRef
20.
Zurück zum Zitat Ho AY, Fan G, Atencio DP et al (2007) Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 69:677–684PubMedCrossRef Ho AY, Fan G, Atencio DP et al (2007) Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 69:677–684PubMedCrossRef
21.
Zurück zum Zitat Hoeller U, Borgmann K, Bonacker M et al (2003) Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol 69:137–144PubMedCrossRef Hoeller U, Borgmann K, Bonacker M et al (2003) Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol 69:137–144PubMedCrossRef
22.
Zurück zum Zitat Kasten-Pisula U, Tastan H, Dikomey E (2005) Huge differences in cellular radiosensitivity due to only very small variations in double-strand break repair capacity. Int J Radiat Biol 81:409–419PubMedCrossRef Kasten-Pisula U, Tastan H, Dikomey E (2005) Huge differences in cellular radiosensitivity due to only very small variations in double-strand break repair capacity. Int J Radiat Biol 81:409–419PubMedCrossRef
23.
Zurück zum Zitat Kodigepalli KM, Dutta PS, Bauckman KA et al (2013) SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS Lett 587:5–516PubMedCentralPubMedCrossRef Kodigepalli KM, Dutta PS, Bauckman KA et al (2013) SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS Lett 587:5–516PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Kuptsova N, Chang-Claude J, Kropp S et al (2008) Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer 122:1333–13339PubMedCrossRef Kuptsova N, Chang-Claude J, Kropp S et al (2008) Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer 122:1333–13339PubMedCrossRef
25.
Zurück zum Zitat Langsenlehner T, Thurner EM, Renner W et al (2014) Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy. Strahlenther Onkol 190:364–369PubMedCrossRef Langsenlehner T, Thurner EM, Renner W et al (2014) Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy. Strahlenther Onkol 190:364–369PubMedCrossRef
26.
Zurück zum Zitat Mangoni M, Bisanzi S, Carozzi F et al (2011) Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys 81:52–58PubMedCrossRef Mangoni M, Bisanzi S, Carozzi F et al (2011) Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys 81:52–58PubMedCrossRef
27.
Zurück zum Zitat Moullan N, Cox DG, Angele S et al (2003) Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12:1168–1174PubMed Moullan N, Cox DG, Angele S et al (2003) Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12:1168–1174PubMed
28.
Zurück zum Zitat Raabe A, Derda K, Reuther S et al (2012) Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol 7:65PubMedCentralPubMedCrossRef Raabe A, Derda K, Reuther S et al (2012) Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol 7:65PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Reuther S, Metzke E, Bonin M et al (2013) No effect of the transforming growth factor beta1 promoter polymorphism C-509T on TGFB1 gene expression, protein secretion, or cellular radiosensitivity. Int J Radiat Oncol Biol Phys 85:460–465PubMedCrossRef Reuther S, Metzke E, Bonin M et al (2013) No effect of the transforming growth factor beta1 promoter polymorphism C-509T on TGFB1 gene expression, protein secretion, or cellular radiosensitivity. Int J Radiat Oncol Biol Phys 85:460–465PubMedCrossRef
30.
Zurück zum Zitat Suga T, Ishikawa A, Kohda M et al (2007) Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 69:685–693PubMedCrossRef Suga T, Ishikawa A, Kohda M et al (2007) Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 69:685–693PubMedCrossRef
31.
Zurück zum Zitat Thurner EM, Krenn-Pilko S, Langsenlehner U et al (2014) Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy. Strahlenther Onkol 190:304–309PubMedCrossRef Thurner EM, Krenn-Pilko S, Langsenlehner U et al (2014) Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy. Strahlenther Onkol 190:304–309PubMedCrossRef
32.
Zurück zum Zitat Turnbull CL, Bacon AL, Dunlop MG et al (2012) In vitro stability of APC gene sequences and the influence of DNA repair status. Mutagenesis 27:233–238PubMedCrossRef Turnbull CL, Bacon AL, Dunlop MG et al (2012) In vitro stability of APC gene sequences and the influence of DNA repair status. Mutagenesis 27:233–238PubMedCrossRef
33.
Zurück zum Zitat Van Den Broeck A, Nissou D, Brambilla E et al (2012) Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis 33:320–325PubMedCrossRef Van Den Broeck A, Nissou D, Brambilla E et al (2012) Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis 33:320–325PubMedCrossRef
34.
Zurück zum Zitat Wellek S, Goddard KA, Ziegler A (2010) A confidence-limit-based approach to the assessment of Hardy-Weinberg equilibrium. Biom J 52:253–570PubMed Wellek S, Goddard KA, Ziegler A (2010) A confidence-limit-based approach to the assessment of Hardy-Weinberg equilibrium. Biom J 52:253–570PubMed
35.
Zurück zum Zitat West CM, Davidson SE, Elyan SA et al (2001) Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 51:10–15PubMedCrossRef West CM, Davidson SE, Elyan SA et al (2001) Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 51:10–15PubMedCrossRef
36.
Zurück zum Zitat West C, Rosenstein BS, Alsner J et al (2010) Establishment of a radiogenomics consortium. Int J Radiat Oncol Biol Phys 76:1295–1296PubMedCrossRef West C, Rosenstein BS, Alsner J et al (2010) Establishment of a radiogenomics consortium. Int J Radiat Oncol Biol Phys 76:1295–1296PubMedCrossRef
37.
Zurück zum Zitat Yang M, Zhang L, Bi N et al (2011) Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 79:1402–1407PubMedCrossRef Yang M, Zhang L, Bi N et al (2011) Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 79:1402–1407PubMedCrossRef
38.
Zurück zum Zitat Zhang Q, Irvin MR, Arnett DK et al (2011) A data-driven method for identifying rare variants with heterogeneous trait effects. Genet Epidemiol 35:679–685PubMedCentralPubMedCrossRef Zhang Q, Irvin MR, Arnett DK et al (2011) A data-driven method for identifying rare variants with heterogeneous trait effects. Genet Epidemiol 35:679–685PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Zschenker O, Raabe A, Boeckelmann IK et al (2010) Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol 97:26–32PubMedCrossRef Zschenker O, Raabe A, Boeckelmann IK et al (2010) Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol 97:26–32PubMedCrossRef
Metadaten
Titel
Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity
verfasst von
Sebastian Reuther, PhD
Silke Szymczak, PhD
Annette Raabe, PhD
Kerstin Borgmann, PhD
Andreas Ziegler, PhD
Cordula Petersen, MD
Prof Dr. Ekkehard Dikomey, PhD
Ulrike Hoeller, MD
Publikationsdatum
01.01.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 1/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0741-y

Weitere Artikel der Ausgabe 1/2015

Strahlentherapie und Onkologie 1/2015 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.